# Study of Cyclosporine in Post-LASIK Patients

> **NCT00991458** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 621 (actual)

## Conditions studied

- Laser In Situ Keratomileusis

## Interventions

- **DRUG:** Cyclosporine 0.010% eye drops
- **DRUG:** Cyclosporine 0.005% eye drops
- **DRUG:** Placebo (Vehicle for Cyclosporine)

## Key facts

- **NCT ID:** NCT00991458
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 621 (ACTUAL)
- **Last updated:** 2013-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991458, "Study of Cyclosporine in Post-LASIK Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00991458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*